Search Team

Search by Last Name
A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z

Fish Litigation Blog

Welcome to the Fish & Richardson litigation blog, a community site where our intellectual property, commercial, and white collar litigators share information on nationwide litigation developments and trends. Join the conversation!

Fish Litigation Blog
Filter blogs by
Webinars

Fish Litigation Blog

The depth and breadth of Fish’s litigation practice is constantly expanding to fit the needs of our clients and the realities of the economic, business, and technological challenges they face. Our litigation blog reflects the full expanse of our litigation practice. Among other things, we discuss: developments in patent and trademark litigation, intricacies associated with ITC proceeding, Federal Circuit summaries and Supreme Court decisions, how courts are handling NPE litigation, various manifestations of the America Invents Act (AIA), commercial and business litigation matters, the Delaware Court of Chancery, and white collar defense and government investigation issues.

q&a 2016

Welcome to the conversation!

 


IP Litigation, Life Sciences
September 21, 2016
FDA to Hold Public Meeting on Biosimilar User Fees
Authors: Rachel Bandli, Tasha M. Francis, Ph.D.
IP Litigation, Life Sciences
September 20, 2016
Amgen Argues “Entire Balance of BPCIA” in Jeopardy unless Federal Circuit Overturns Discovery Ruling
Authors: Holly Chamberlain, Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
IP Litigation, Life Sciences
September 19, 2016
The Dance Continues: Apotex Petitions the Supreme Court for Review
Authors: Will Orlady, Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
IP Litigation
September 16, 2016
My Intellectual Property Licensor is Bankrupt – Now What?
Author: John R. Lane
September 12, 2016
District Courts Appear to Defer, Even Post-Halo, to Juries’ Willfulness Findings
Author: Phillip W. Goter
IP Litigation, Life Sciences
September 8, 2016
Amgen Loses BPCIA Suit Against Apotex’s Neulasta® and Neupogen® Biosimilars
Authors: Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
IP Litigation, Life Sciences
August 31, 2016
FDA Approves Sandoz's Biosimilar of Enbrel®
Authors: Jenny Shmuel, Ph.D., Tasha M. Francis, Ph.D.
Cybersecurity
August 29, 2016
Short-Sellers Partnering with Hackers: Exploiting Cybersecurity Fears for Short-Term Profit
Author: Caroline K. Simons
IP Litigation, Life Sciences
August 25, 2016
Court Invalidates Janssen Remicade® Patent for Double Patenting; Celltrion Seeks Speedy Appeal
Authors: Rachel Bandli, Jenny Shmuel, Ph.D.
Commercial Litigation
August 25, 2016
The Interplay of the Defend Trade Secrets Act, Inevitable Disclosure, and Non-Competes
Author: Caroline K. Simons
IP Litigation, Federal Circuit
August 16, 2016
Federal Circuit Once Again Finds That a Functional Claim Term is Indefinite Even Without the Use of “Means.”
Author: David B. Conrad
load more posts

Stay current with Fish Sign up for our Newsletter